E.V. Dementeva1, O.I. Kaganov2, 3, I.B. Ermakov1
1Meditsinskaya Kompaniya IDK JSC, Samara
2Samara Regional Clinical Oncological Dispensary, Samara
3Samara State Medical University, Samara
Dementeva E.V. – oncologist of the Department of Antitumor Therapy
29 Entuziastov St., 443067, Samara, Russian Federation, tel.: +7-917-152-21-27, e-mail: dementeva.ek98@mail.ru, ORCID ID: 0000-0001-9361-6354
Abstract. About one million new cases of gastric cancer are detected worldwide every year, with about 40% in the advanced stage of the disease, as there are no specific symptoms. The main method of treatment for metastatic and unresectable gastric cancer is systemic chemotherapy. At the present stage of oncology development, the choice of medication treatment is rather limited.
The review presents a clinical case of long-term intermittent use of first line chemotherapy in a patient with metastatic HER2 negative gastric cancer.
Key words: gastric cancer, chemotherapy, FOLFOX, first-line therapy.